INTRODUCTION

Decreased vision in patients with gyrate atrophy (GA) may be due to retinal atrophy, cataract development or macular edema\(^1\). Treatment options for GA remain limited. Intravitreal triamcinolone acetonide (IVTA) has gained projection as a promising therapeutic modality for a wide range of retinal diseases\(^2\), but its use in GA-related macular edema has not been reported yet. This paper aims to prospectively describe the use of 4 mg intravitreal triamcinolone acetonide for gyrate atrophy-related macular edema and to report the anatomic and functional results, during a nine-month period.

CASE REPORT

A 27-year-old female had a diagnosis of gyrate atrophy for six years and sought the university hospital complaining of decreased vision in both eyes. She had been previously treated with topical ketorolac tromethamine associated with topical prednisolone and oral acetazolamide for six weeks,
Macular edema associated with gyrate atrophy managed with intravitreal triamcinolone: a case report

with no improvement. At presentation, best-corrected visual acuity (BCVA) was 20/100 in OD and 20/80 in OS. Anterior segment examination disclosed significant anterior and posterior subcapsular cataract in OD and an in-the-bag intraocular lens, with a Nd:YAG laser posterior capsulotomy in OS. Fundus examination showed typical GA findings (Figure 1A). Fluorescein angiography (FA) disclosed slight late foveal leakage (Figure 1B) and optical coherence tomography (OCT) revealed marked macular edema and foveal serous detachment in both eyes (Figures 1C, D and 2A). The patient consented to go through IVTA (Kenalog-40; Bristol Myers Squibb Princeton, New Jersey, USA) injection in OS. One month later, BCVA improved to 20/50 +1, FA showed decrease in leakage and OCT revealed some reduction of edema, with total macular volume (TMV) decreasing from 8.94 mm³ to 7.09 mm³ and central macular thickness (CMT) from 382 ± 6 µm to 362 ± 3 µm (Figure 2B). After three months, BCVA was maintained (20/50 +3) and FA images were similar to those at one month postinjection. Nevertheless, foveal edema partially recurred as revealed by OCT (TMV = 7.55 mm³ and CMT = 427 ± 0 µm (Figure 2C). Examination six months after injection showed stable BCVA in OS (20/50 +3), but an additional increase in macular edema to a level similar to that before IVTA injection (CMT = 435 ± 4 µm and TMV = 8.8 mm³), as depicted in Figure 2D. Final examination at nine months showed a drop in BCVA to 20/80 +1, and maintenance of macular edema, although with a slightly different macular profile than that of the baseline (CMT = 406 µm, TMV = 9.07 mm³) - Figure 2E. Intraocular pressure was normal all over the follow-up.

DISCUSSION

The mechanism of macular edema in this subset appears to be related to malfunction of outer blood-retinal barrier, with diffusion of fluid towards intraretinal and subretinal spaces. It is possible that this involves an underlying autoimmune process3,4. IVTA use in retinal dystrophies has led to some controversy3,5. The decision to perform IVTA injection in this patient was based on failure of previous clinical treatment. OS was selected for injection because of its better media transparency compared to OD, in which there was significant lens opacity. That would allow sharper images of the macula on FA and OCT and also a more accurate evaluation of BCVA. Moreover IVTA injection carries the risk of cataract worsening.

Reduction in CMT and, particularly, in TMV were observed one month after injection. Nevertheless, OCT images at three and six months showed an even thicker macula center than that of the baseline. TMV was maintained nonetheless. It is important to notice that a variation of up to 10 µm in retinal thickness of normal subjects measured on OCT shall not be considered significant, due to limited resolution of the device5). Probably the fluctuations in CMT and TMV herein described may be due to fluid redistribution and macular remodeling. Other possibilities could have been rebound effect or natural progression of the edema. This outcome was not as good as those reported in eyes with retinitis pigmentosa3,5 and other exudative diseases2,6, in which total resorption of edema, with recovery of foveal depression is usually achieved, at least for some time. In fact, most of these exudative diseases show incompetence of inner hemato-retinal barrier, that can be stabilized with IVTA2,5. It is possible that the outer hemato-retinal barrier affected in GA and retinitis pigmentosa, for instance, may be less susceptible to IVTA-mediated stabilization. Eventual influence of previous cataract surgery and posterior capsulotomy on our results is unknown. The reason for the stable visual acuity despite anatomic worsening until the 6th month visit also remains speculative, although at the last examination, nine months after injection, BCVA dropped to a level similar to that of the baseline. It is possible that variable photoreceptor dysfunction may interfere with the correlation between macular edema disclosed by OCT and BCVA in gyrate atrophy. In diabetic macular edema, correlation between foveal thickness and visual acuity following IVTA has also been reported as not strong7. Subjective component of visual acuity testing should also be considered, even though patient information was sharp and examination was performed by the same physician (DVVS) at all time points. Moreover, refraction in the treated eye was also stable (-0.75-1.00x135°) until the last

Figure 1 - Baseline features. A) OS fundus photograph, showing typical confluent patches of chorioretinal atrophy and pigment clumping, with an altered foveal reflex. B) OS late-phase fluorescein angiography, with faint perifoveal hyperfluorescence. C and D) OCT showing macular edema and foveal detachment in OD and OS, respectively.
Macular edema associated with gyrate atrophy managed with intravitreal triamcinolone: a case report

Figure 2 - OS OCT findings and corresponding best-corrected visual acuity at each time point. A) Baseline, with macular edema and subfoveal fluid. B) One month after IVTA injection, showing more demarcation of cystic spaces and edema of less magnitude and extension. C) Three months after IVTA, with partial recrudescence of subretinal fluid. D) Six months after IVTA, with more fluid pooling under the fovea. E) Final examination at nine months, showing slight change in macular profile, but a similar amount of edema.
follow-up visit. Further sequential physiologic testing such as visual field or contrast sensitivity examinations would have shed more light on this subject.

To our knowledge, this is the first case of GA-related macular edema treated with IVTA in the indexed literature. It shows a slight and transient therapeutic effect on resorption of intraretinal fluid, which might lead to a better central vision. Nevertheless, after drug clearance, edema may have a tendency to recur, with decrease in BCVA to pretreatment level. Further studies are needed to clarify this issue.

RESUMO

Objetivo: Descrever o uso de acetonida de triancinolona intravítrea (TAIV) em caso de edema macular (EM) associado a atrofia girata (AG). Relato do caso: Paciente de 27 anos, do sexo feminino, queixava-se de baixa de visão desde o diagnóstico de AG, há seis anos. À admissão, apresentava acuidade visual corrigida de 20/100 no OD e 20/80 no OE. Exame oftalmológico revelava catarata significativa no OD, pseudofacia no OE e achados típicos de AG. Angiografia fluoresceínica (AFG) mostrou EM, confirmado pela tomografia de coerência óptica (OCT), que também revelou líquido subfoveal. Foi então realizada injeção de 4 mg de TAIV no OE. Após um mês, a visão melhorou para 20/50+1 e a espessura foveal se reduziu, com menos extravasamento à AFG. Esse quadro foi mantido até os seis meses, quando houve recorrência do edema macular em nível semelhante ao inicial. Aos nove meses, a visão retornou a 20/80 e o edema se manteve, com remodelamento no perfil macular. Conclusão: A injeção de 4 mg de TAIV tem efeito transitório no EM associado a AG. Após a eliminação da droga, há recorrência do EM, com retorno da visão aos níveis pré-tratamento.

Descritores: Atrofia girata/quimioterapia; Edema macular cistoide/quimioterapia; Triancinolona acetonida/uso terapêutico; Case reports [Publication type]

REFERENCES